Scroll

eletriptan 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
serotonin (5-HT1) receptor agonists, sumatriptan derivatives	995	143322-58-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: eletriptan eletriptan hydrobromide UK 116044-04 UK-116,044 relpax	Eletriptan binds with high affinity to 5-HT1B, 5-HT1D and 5-HT1F receptors, has modest affinity for 5-HT1A, 5-HT1E, 5-HT2B and 5-HT7 receptors. Migraines are likely due to local cranial vasodilatation and/or to the release of sensory neuropeptides (vasoactive intestinal peptide, substance P and calcitonin gene-related peptide) through nerve endings in the trigeminal system. The therapeutic activity of Eletriptan for the treatment of migraine headache is thought to be due to the agonist effects at the 5-HT1B/1D receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release. Molecular weight: 382.52 Formula: C22H26N2O2S CLOGP: 3.36 LIPINSKI: 0 HAC: 4 HDO: 1 TPSA: 53.17 ALOGS: -5.51 ROTB: 6 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

eletriptan
eletriptan hydrobromide
UK 116044-04
UK-116,044
relpax

Eletriptan binds with high affinity to 5-HT1B, 5-HT1D and 5-HT1F receptors, has modest affinity for 5-HT1A, 5-HT1E, 5-HT2B and 5-HT7 receptors. Migraines are likely due to local cranial vasodilatation and/or to the release of sensory neuropeptides (vasoactive intestinal peptide, substance P and calcitonin gene-related peptide) through nerve endings in the trigeminal system. The therapeutic activity of Eletriptan for the treatment of migraine headache is thought to be due to the agonist effects at the 5-HT1B/1D receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.

Molecular weight: 382.52
Formula: C22H26N2O2S
CLOGP: 3.36
LIPINSKI: 0
HAC: 4
HDO: 1
TPSA: 53.17
ALOGS: -5.51
ROTB: 6

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
40	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	4 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	5 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	1.49 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	1.60 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	5.30 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.15 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	4.20 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Dec. 26, 2002	FDA	PFIZER IRELAND

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Migraine	211.95	16.73	144	8115	103202	63377561
Rheumatoid factor negative	79.71	16.73	18	8241	593	63480170
Recalled product administered	76.88	16.73	17	8242	508	63480255
Medication overuse headache	74.18	16.73	18	8241	814	63479949
Headache	60.63	16.73	200	8059	633041	62847722
Drug dependence	59.47	16.73	38	8221	24445	63456318
Drug ineffective	53.07	16.73	271	7988	1044494	62436269
Serotonin syndrome	42.72	16.73	33	8226	28649	63452114
Hepatic infiltration eosinophilic	38.67	16.73	6	8253	21	63480742
Feeling abnormal	37.07	16.73	68	8191	148324	63332439
Paraesthesia	35.58	16.73	69	8190	156897	63323866
Intentional product misuse	34.38	16.73	41	8218	60876	63419887
Withdrawal syndrome	29.75	16.73	23	8236	19974	63460789
Throat tightness	29.37	16.73	25	8234	24862	63455901
Reversible cerebral vasoconstriction syndrome	27.41	16.73	11	8248	2647	63478116
Pleural rub	26.77	16.73	5	8254	62	63480701
Lichen planus	25.24	16.73	10	8249	2328	63478435
Product dispensing error	25.03	16.73	16	8243	10289	63470474
Joint swelling	24.94	16.73	6	8253	327660	63153103
Oral mucosal exfoliation	24.82	16.73	9	8250	1645	63479118
Vomiting	24.63	16.73	140	8119	559477	62921286
Drug abuse	21.69	16.73	36	8223	72482	63408281
Death	21.42	16.73	11	8248	374370	63106393
Basilar migraine	21.24	16.73	4	8255	52	63480711
Anxiety	20.90	16.73	69	8190	217472	63263291
Neck pain	20.18	16.73	34	8225	69284	63411479
Vasoconstriction	20.17	16.73	6	8253	590	63480173
Cholecystitis chronic	20.13	16.73	14	8245	10347	63470416
Chest discomfort	19.80	16.73	44	8215	109925	63370838
Cerebral vasoconstriction	19.74	16.73	7	8252	1201	63479562
Disturbance in attention	18.79	16.73	24	8235	38165	63442598
Therapeutic product effect incomplete	18.14	16.73	46	8213	125010	63355753
Communication disorder	17.95	16.73	8	8251	2492	63478271
Blindness transient	17.74	16.73	9	8250	3735	63477028
Drug abuser	16.76	16.73	8	8251	2915	63477848

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Medication overuse headache	85.43	32.26	12	874	130	34955915
Drug abuse	68.47	32.26	38	848	99058	34856987
Insomnia	46.05	32.26	30	856	103877	34852168
Therapy partial responder	43.06	32.26	14	872	9602	34946443
Drug dependence	40.23	32.26	17	869	24200	34931845
Paraesthesia	37.17	32.26	22	864	64150	34891895

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Migraine	215.43	18.75	118	6727	87375	79650168
Medication overuse headache	130.90	18.75	27	6818	885	79736658
Drug ineffective	82.49	18.75	240	6605	1080673	78656870
Headache	82.36	18.75	176	6669	653596	79083947
Recalled product administered	81.31	18.75	18	6827	829	79736714
Rheumatoid factor negative	70.31	18.75	17	6828	1156	79736387
Drug dependence	53.84	18.75	37	6808	40732	79696811
Drug abuse	50.67	18.75	66	6779	162625	79574918
Paraesthesia	40.72	18.75	62	6783	176261	79561282
Feeling abnormal	31.27	18.75	52	6793	159147	79578396
Reversible cerebral vasoconstriction syndrome	30.36	18.75	11	6834	3046	79734497
Intentional product misuse	30.21	18.75	39	6806	95126	79642417
Therapeutic product effect incomplete	30.17	18.75	48	6797	141597	79595946
Vomiting	29.53	18.75	124	6721	665704	79071839
Serotonin syndrome	29.39	18.75	27	6818	45000	79692543
Throat tightness	29.21	18.75	22	6823	27885	79709658
Pleural rub	28.63	18.75	5	6840	65	79737478
Pain	28.10	18.75	127	6718	703675	79033868
Acute kidney injury	26.66	18.75	6	6839	519398	79218145
Oral mucosal exfoliation	25.25	18.75	8	6837	1477	79736066
Product dispensing error	24.83	18.75	15	6830	13248	79724295
Death	24.56	18.75	9	6836	566505	79171038
Drug hypersensitivity	24.07	18.75	68	6777	298848	79438695
Status migrainosus	22.13	18.75	4	6841	64	79737479
Basilar migraine	22.07	18.75	4	6841	65	79737478
Withdrawal syndrome	21.32	18.75	18	6827	26836	79710707
Stress	21.25	18.75	30	6815	79582	79657961
Lichen planus	20.31	18.75	8	6837	2783	79734760
Rubber sensitivity	20.05	18.75	7	6838	1742	79735801
Breast pain	19.87	18.75	11	6834	8254	79729289
Chest discomfort	19.36	18.75	39	6806	138005	79599538

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N02CC06	NERVOUS SYSTEM ANALGESICS ANTIMIGRAINE PREPARATIONS Selective serotonin (5HT1) agonists
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018490	Serotonin Agents
MeSH PA	D017366	Serotonin Receptor Agonists
FDA MoA	N0000175763	Serotonin 1b Receptor Agonists
FDA MoA	N0000175764	Serotonin 1d Receptor Agonists
FDA EPC	N0000175765	Serotonin-1b and Serotonin-1d Receptor Agonist
CHEBI has role	CHEBI:35475	non-steroidal anti-inflammatory agent
CHEBI has role	CHEBI:35941	serotonin agonists

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Migraine	indication	37796009	DOID:6364
Hypercholesterolemia	contraindication	13644009
Myocardial infarction	contraindication	22298006	DOID:5844
Coronary artery spasm	contraindication	23687008	DOID:11840
Hypertensive disorder	contraindication	38341003	DOID:10763
Hemiplegic migraine	contraindication	59292006
Hepatic failure	contraindication	59927004
Diabetes mellitus	contraindication	73211009	DOID:9351
Vascular insufficiency of intestine	contraindication	82196007
Prinzmetal angina	contraindication	87343002
Angina pectoris	contraindication	194828000
Cerebrovascular accident	contraindication	230690007
Disease of liver	contraindication	235856003	DOID:409
Transient ischemic attack	contraindication	266257000	DOID:224
Raynaud's phenomenon	contraindication	266261006
Cerebral ischemia	contraindication	287731003
Serotonin syndrome	contraindication	371089000
Cardiovascular event risk	contraindication	395112001
Peripheral vascular disease	contraindication	400047006
Disorder of coronary artery	contraindication	414024009
Myocardial ischemia	contraindication	414795007	DOID:3393
Obesity	contraindication	414916001	DOID:9970
Hypertensive urgency	contraindication	443482000
Smokes tobacco daily	contraindication	449868002
Familial History of Cardiovascular Disease	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.9	acidic
pKa2	8.57	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
5-hydroxytryptamine receptor 1B	GPCR	P28222	5HT1B_HUMAN	AGONIST	Kd	8.52	CHEMBL	CHEMBL
5-hydroxytryptamine receptor 1D	GPCR	P28221	5HT1D_HUMAN	AGONIST	Kd	9.05	CHEMBL	CHEMBL
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN	AGONIST	Ki	7.40	IUPHAR
5-hydroxytryptamine receptor 1F	GPCR	P30939	5HT1F_HUMAN	AGONIST	Ki	8	IUPHAR
5-hydroxytryptamine receptor 1E	GPCR	P28566	5HT1E_HUMAN	AGONIST	Ki	7.20	IUPHAR

External reference:

ID	Source
4021372	VUID
N0000148791	NUI
D01973	KEGG_DRUG
177834-92-3	SECONDARY_CAS_RN
4021372	VANDF
C0759933	UMLSCUI
CHEBI:50922	CHEBI
CHEMBL1510	ChEMBL_ID
DB00216	DRUGBANK_ID
CHEMBL1201003	ChEMBL_ID
C115647	MESH_SUPPLEMENTAL_RECORD_UI
77993	PUBCHEM_CID
40	IUPHAR_LIGAND_ID
7426	INN_ID
22QOO9B8KI	UNII
231049	RXNORM
17144	MMSL
260414	MMSL
46299	MMSL
d04849	MMSL
009521	NDDF
009522	NDDF
395255007	SNOMEDCT_US
410843003	SNOMEDCT_US
425436002	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Relpax	HUMAN PRESCRIPTION DRUG LABEL	1	0049-2330	TABLET, FILM COATED	20 mg	ORAL	NDA	29 sections
Relpax	HUMAN PRESCRIPTION DRUG LABEL	1	0049-2330	TABLET, FILM COATED	20 mg	ORAL	NDA	29 sections
Relpax	HUMAN PRESCRIPTION DRUG LABEL	1	0049-2340	TABLET, FILM COATED	40 mg	ORAL	NDA	29 sections
Relpax	HUMAN PRESCRIPTION DRUG LABEL	1	0049-2340	TABLET, FILM COATED	40 mg	ORAL	NDA	29 sections
Eletriptan Hydrobromide	HUMAN PRESCRIPTION DRUG LABEL	1	0093-8310	TABLET, FILM COATED	20 mg	ORAL	ANDA	25 sections
Eletriptan Hydrobromide	HUMAN PRESCRIPTION DRUG LABEL	1	0093-8310	TABLET, FILM COATED	20 mg	ORAL	ANDA	25 sections
Eletriptan Hydrobromide	HUMAN PRESCRIPTION DRUG LABEL	1	0093-8310	TABLET, FILM COATED	20 mg	ORAL	ANDA	25 sections
Eletriptan Hydrobromide	HUMAN PRESCRIPTION DRUG LABEL	1	0093-8311	TABLET, FILM COATED	40 mg	ORAL	ANDA	25 sections
Eletriptan Hydrobromide	HUMAN PRESCRIPTION DRUG LABEL	1	0093-8311	TABLET, FILM COATED	40 mg	ORAL	ANDA	25 sections
Eletriptan Hydrobromide	HUMAN PRESCRIPTION DRUG LABEL	1	0093-8311	TABLET, FILM COATED	40 mg	ORAL	ANDA	25 sections
Eletriptan Hydrobromide	HUMAN PRESCRIPTION DRUG LABEL	1	0378-4287	TABLET, FILM COATED	20 mg	ORAL	ANDA	26 sections
Eletriptan Hydrobromide	HUMAN PRESCRIPTION DRUG LABEL	1	0378-4288	TABLET, FILM COATED	40 mg	ORAL	ANDA	26 sections
Relpax	HUMAN PRESCRIPTION DRUG LABEL	1	16590-201	TABLET, FILM COATED	40 mg	ORAL	NDA	28 sections
Relpax	HUMAN PRESCRIPTION DRUG LABEL	1	21695-871	TABLET, FILM COATED	40 mg	ORAL	NDA	28 sections
eletriptan hydrobromide	Human Prescription Drug Label	1	27241-039	TABLET, FILM COATED	20 mg	ORAL	ANDA	24 sections
eletriptan hydrobromide	Human Prescription Drug Label	1	27241-040	TABLET, FILM COATED	40 mg	ORAL	ANDA	24 sections
Relpax	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5528	TABLET, FILM COATED	40 mg	ORAL	NDA	28 sections
eletriptan hydrobromide	Human Prescription Drug Label	1	55700-756	TABLET, FILM COATED	40 mg	ORAL	ANDA	24 sections
Eletriptan Hydrobromide	Human Prescription Drug Label	1	59651-104	TABLET, FILM COATED	20 mg	ORAL	ANDA	24 sections
Eletriptan Hydrobromide	Human Prescription Drug Label	1	59651-105	TABLET, FILM COATED	40 mg	ORAL	ANDA	24 sections
Eletriptan	HUMAN PRESCRIPTION DRUG LABEL	1	59762-2321	TABLET, FILM COATED	20 mg	ORAL	NDA AUTHORIZED GENERIC	26 sections
Eletriptan	HUMAN PRESCRIPTION DRUG LABEL	1	59762-2321	TABLET, FILM COATED	20 mg	ORAL	NDA AUTHORIZED GENERIC	26 sections
Eletriptan	HUMAN PRESCRIPTION DRUG LABEL	1	59762-2322	TABLET, FILM COATED	40 mg	ORAL	NDA AUTHORIZED GENERIC	26 sections
Eletriptan	HUMAN PRESCRIPTION DRUG LABEL	1	59762-2322	TABLET, FILM COATED	40 mg	ORAL	NDA AUTHORIZED GENERIC	26 sections
Eletriptan Hydrobromide	HUMAN PRESCRIPTION DRUG LABEL	1	63629-8320	TABLET, FILM COATED	40 mg	ORAL	ANDA	24 sections
Eletriptan hydrobromide	HUMAN PRESCRIPTION DRUG LABEL	1	68382-922	TABLET, FILM COATED	20 mg	ORAL	ANDA	24 sections
Eletriptan hydrobromide	HUMAN PRESCRIPTION DRUG LABEL	1	68382-923	TABLET, FILM COATED	40 mg	ORAL	ANDA	24 sections
Eletriptan hydrobromide	HUMAN PRESCRIPTION DRUG LABEL	1	70771-1107	TABLET, FILM COATED	20 mg	ORAL	ANDA	1 sections
Eletriptan hydrobromide	HUMAN PRESCRIPTION DRUG LABEL	1	70771-1107	TABLET, FILM COATED	20 mg	ORAL	ANDA	1 sections
Eletriptan hydrobromide	HUMAN PRESCRIPTION DRUG LABEL	1	70771-1108	TABLET, FILM COATED	40 mg	ORAL	ANDA	1 sections